This inventor holds 1 USPTO granted patent. Top assignee: Shanghai Cell Therapy Group Co., Ltd.. Active years: 2025.
Company Filing History:
Years Active: 2025
Title: Duqing Jiang - Innovator in Cell Therapy
Introduction
Duqing Jiang is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of cell therapy, particularly in the development of innovative treatments for malignant tumors. His work focuses on enhancing the efficacy of T cell therapies through advanced genetic modifications.
Latest Patents
Duqing Jiang holds a patent for an "Antibody-modified chimeric antigen receptor modified T cell and uses thereof." This invention involves a T cell that expresses an antibody or contains the coding sequence of the antibody. The antibody includes an optional signal peptide, an antigen binding sequence, and a mutant type Fc segment. The mutant type Fc segment features specific amino acid mutations at the 17th and 79th sites of the IgG4 Fc segment. Notably, the T cell is preferably a CAR-T cell, which is utilized in treating malignant tumors.
Career Highlights
Duqing Jiang is associated with Shanghai Cell Therapy Group Co., Ltd., where he applies his expertise in cell therapy and innovative treatments. His work has positioned him as a key figure in the advancement of therapeutic strategies for cancer treatment.
Collaborations
Duqing Jiang collaborates with notable colleagues, including Qijun Qian and Huajun Jin. Their combined efforts contribute to the ongoing research and development in the field of cell therapy.
Conclusion
Duqing Jiang's innovative work in antibody-modified T cells represents a significant advancement in cancer treatment. His contributions continue to shape the future of cell therapy and improve patient outcomes.